Neuregulin-1 (NRG1) is a multifaceted growth factor that plays a pivotal role in neural development, synaptic plasticity and neurotransmission. Extensive research implicates disruptions in the ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted fast track designation to zenocutuzumab for treatment of patients with metastatic solid tumors ...
A phase III trial of tumor-treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3. Background: NRG1 (Neuregulin-1) ...
Neuregulin-1 (NRG1) fusions are rare but actionable oncogenic drivers in solid tumors. Seribantumab is a fully human anti-HER3 IgG2 monoclonal antibody. In this report, we present the antitumor ...
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins. The ...
Recent US Food and Drug Administration approvals—including amivantamab, an epidermal growth factor receptor (EGFR)/mesenchymal-epithelial transition factor–targeting monoclonal antibody for EGFR exon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results